Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells

EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients is inevitable. Identification of resistance mechanisms and corresponding targeting strategies can lead to more successful later-line treatment in many patients. Using spectrometry-based proteomics, we iden...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:NPJ Precis Oncol
Glavni autori: Terp, Mikkel G., Jacobsen, Kirstine, Molina, Miguel Angel, Karachaliou, Niki, Beck, Hans C., Bertran-Alamillo, Jordi, Giménez-Capitán, Ana, Cardona, Andrés F., Rosell, Rafael, Ditzel, Henrik J.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282882/
https://ncbi.nlm.nih.gov/pubmed/34267282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00208-w
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items